Artivion, Inc. (NYSE: AORT) Stock Competitors & Peer Comparison
See AORT's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AORT and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AORT | $22.86 | -0.39% | 1.1B | 38.07 | $0.60 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $100.95 | -0.03% | 174.7B | 19.37 | $5.21 | +2.46% |
| MDT | $87.09 | -2.69% | 111.5B | 15.75 | $5.53 | +3.22% |
| SYK | $278.77 | +1.26% | 106.9B | 20.83 | $13.39 | +1.27% |
| BSX | $43.88 | -0.52% | 65.2B | 14.15 | $3.10 | N/A |
| EW | $88.08 | +1.44% | 50.7B | 32.63 | $2.70 | N/A |
| DXCM | $86.64 | -0.05% | 32.7B | 33.98 | $2.55 | N/A |
| GEHC | $66.46 | -0.48% | 30B | 14.57 | $4.56 | +0.21% |
| PHG | $24.77 | -1.35% | 24.2B | 14.15 | $1.75 | +3.94% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
AORT vs BSX-PA Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, AORT's ROE is -0.01%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, AORT is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for AORT.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
AORT vs ABT Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ABT has a market cap of 174.7B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ABT trades at $100.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ABT's P/E ratio is 19.37. In terms of profitability, AORT's ROE is -0.01%, compared to ABT's ROE of +0.11%. Regarding short-term risk, AORT is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ABT's competition here
Medtronic plc (NYSE: MDT)
AORT vs MDT Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, MDT has a market cap of 111.5B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while MDT trades at $87.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas MDT's P/E ratio is 15.75. In terms of profitability, AORT's ROE is -0.01%, compared to MDT's ROE of +0.11%. Regarding short-term risk, AORT is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for AORT.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
AORT vs SYK Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, SYK has a market cap of 106.9B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while SYK trades at $278.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas SYK's P/E ratio is 20.83. In terms of profitability, AORT's ROE is -0.01%, compared to SYK's ROE of +0.16%. Regarding short-term risk, AORT is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for AORT.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
AORT vs BSX Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, BSX has a market cap of 65.2B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while BSX trades at $43.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas BSX's P/E ratio is 14.15. In terms of profitability, AORT's ROE is -0.01%, compared to BSX's ROE of +0.15%. Regarding short-term risk, AORT is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for AORT.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
AORT vs EW Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, EW has a market cap of 50.7B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while EW trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas EW's P/E ratio is 32.63. In terms of profitability, AORT's ROE is -0.01%, compared to EW's ROE of +0.10%. Regarding short-term risk, AORT is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for AORT.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
AORT vs DXCM Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while DXCM trades at $86.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas DXCM's P/E ratio is 33.98. In terms of profitability, AORT's ROE is -0.01%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, AORT is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for AORT.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
AORT vs GEHC Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, GEHC has a market cap of 30B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while GEHC trades at $66.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas GEHC's P/E ratio is 14.57. In terms of profitability, AORT's ROE is -0.01%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, AORT is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for AORT.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
AORT vs PHG Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, PHG has a market cap of 24.2B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while PHG trades at $24.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas PHG's P/E ratio is 14.15. In terms of profitability, AORT's ROE is -0.01%, compared to PHG's ROE of +0.10%. Regarding short-term risk, AORT is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for AORT.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
AORT vs ZBH Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ZBH trades at $91.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ZBH's P/E ratio is 10.77. In terms of profitability, AORT's ROE is -0.01%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, AORT is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
AORT vs ABMD Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ABMD's P/E ratio is 65.36. In terms of profitability, AORT's ROE is -0.01%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, AORT is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ABMD's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
AORT vs SWAV Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas SWAV's P/E ratio is 78.76. In terms of profitability, AORT's ROE is -0.01%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, AORT is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SWAV's competition here
Penumbra, Inc. (NYSE: PEN)
AORT vs PEN Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while PEN trades at $318.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas PEN's P/E ratio is 83.26. In terms of profitability, AORT's ROE is -0.01%, compared to PEN's ROE of +0.11%. Regarding short-term risk, AORT is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for AORT.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
AORT vs SNN Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, SNN has a market cap of 11.3B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while SNN trades at $26.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas SNN's P/E ratio is 18.19. In terms of profitability, AORT's ROE is -0.01%, compared to SNN's ROE of +0.12%. Regarding short-term risk, AORT is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SNN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
AORT vs BIO-B Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while BIO-B trades at $385.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, AORT's ROE is -0.01%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, AORT is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for AORT.Check BIO-B's competition here
Align Technology, Inc. (NASDAQ: ALGN)
AORT vs ALGN Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ALGN has a market cap of 10.3B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ALGN trades at $144.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ALGN's P/E ratio is 13.13. In terms of profitability, AORT's ROE is -0.01%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, AORT is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for AORT.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
AORT vs BIO Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while BIO trades at $379.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas BIO's P/E ratio is 40.90. In terms of profitability, AORT's ROE is -0.01%, compared to BIO's ROE of +0.03%. Regarding short-term risk, AORT is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for AORT.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
AORT vs GMED Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, GMED has a market cap of 10.2B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while GMED trades at $75.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas GMED's P/E ratio is 17.06. In terms of profitability, AORT's ROE is -0.01%, compared to GMED's ROE of +0.12%. Regarding short-term risk, AORT is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for AORT.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKR)
AORT vs BRKR Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, BRKR has a market cap of 9.8B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while BRKR trades at $64.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas BRKR's P/E ratio is 32.42. In terms of profitability, AORT's ROE is -0.01%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, AORT is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for AORT.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
AORT vs BRKRP Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, BRKRP has a market cap of 9.5B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while BRKRP trades at $470.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas BRKRP's P/E ratio is 256.72. In terms of profitability, AORT's ROE is -0.01%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, AORT is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for AORT.Check BRKRP's competition here
Masimo Corporation (NASDAQ: MASI)
AORT vs MASI Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas MASI's P/E ratio is 44.43. In terms of profitability, AORT's ROE is -0.01%, compared to MASI's ROE of +0.09%. Regarding short-term risk, AORT is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for AORT.Check MASI's competition here
Glaukos Corporation (NYSE: GKOS)
AORT vs GKOS Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, GKOS has a market cap of 9.4B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while GKOS trades at $158.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas GKOS's P/E ratio is -184.34. In terms of profitability, AORT's ROE is -0.01%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, AORT is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for AORT.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
AORT vs PODD Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, PODD has a market cap of 9.2B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while PODD trades at $132.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas PODD's P/E ratio is 22.63. In terms of profitability, AORT's ROE is -0.01%, compared to PODD's ROE of +0.27%. Regarding short-term risk, AORT is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check PODD's competition here
Haemonetics Corporation (NYSE: HAE)
AORT vs HAE Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while HAE trades at $105.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas HAE's P/E ratio is 21.13. In terms of profitability, AORT's ROE is -0.01%, compared to HAE's ROE of +0.11%. Regarding short-term risk, AORT is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for AORT.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
AORT vs NARI Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas NARI's P/E ratio is -59.24. In terms of profitability, AORT's ROE is -0.01%, compared to NARI's ROE of -0.00%. Regarding short-term risk, AORT is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for AORT.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
AORT vs ITGR Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ITGR trades at $126.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ITGR's P/E ratio is 19.90. In terms of profitability, AORT's ROE is -0.01%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, AORT is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
AORT vs LIVN Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while LIVN trades at $76.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas LIVN's P/E ratio is 18.29. In terms of profitability, AORT's ROE is -0.01%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, AORT is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for AORT.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
AORT vs IRTC Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while IRTC trades at $114.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas IRTC's P/E ratio is -265.63. In terms of profitability, AORT's ROE is -0.01%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, AORT is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for AORT.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
AORT vs AXNX Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas AXNX's P/E ratio is -709.80. In terms of profitability, AORT's ROE is -0.01%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, AORT is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for AORT.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
AORT vs TMDX Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while TMDX trades at $84.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas TMDX's P/E ratio is 42.68. In terms of profitability, AORT's ROE is -0.01%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, AORT is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for AORT.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
AORT vs NEOG Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, NEOG has a market cap of 2.8B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while NEOG trades at $12.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas NEOG's P/E ratio is 45.46. In terms of profitability, AORT's ROE is -0.01%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, AORT is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for AORT.Check NEOG's competition here
Butterfly Network, Inc. (NYSE: BFLY)
AORT vs BFLY Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while BFLY trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas BFLY's P/E ratio is -37.90. In terms of profitability, AORT's ROE is -0.01%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, AORT is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for AORT.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
AORT vs UFPT Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while UFPT trades at $296.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas UFPT's P/E ratio is 30.33. In terms of profitability, AORT's ROE is -0.01%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, AORT is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for AORT.Check UFPT's competition here
AxoGen, Inc. (NASDAQ: AXGN)
AORT vs AXGN Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while AXGN trades at $42.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas AXGN's P/E ratio is 111.68. In terms of profitability, AORT's ROE is -0.01%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, AORT is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for AORT.Check AXGN's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
AORT vs INSP Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, INSP has a market cap of 2.1B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while INSP trades at $73.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas INSP's P/E ratio is 32.26. In terms of profitability, AORT's ROE is -0.01%, compared to INSP's ROE of +0.18%. Regarding short-term risk, AORT is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for AORT.Check INSP's competition here
NuVasive, Inc. (NASDAQ: NUVA)
AORT vs NUVA Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas NUVA's P/E ratio is 75.00. In terms of profitability, AORT's ROE is -0.01%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, AORT is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for AORT.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
AORT vs ESTA Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ESTA trades at $63.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ESTA's P/E ratio is -50.56. In terms of profitability, AORT's ROE is -0.01%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, AORT is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for AORT.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
AORT vs NVCR Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while NVCR trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas NVCR's P/E ratio is -12.30. In terms of profitability, AORT's ROE is -0.01%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, AORT is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for AORT.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
AORT vs ATEC Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ATEC trades at $10.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ATEC's P/E ratio is -172.83. In terms of profitability, AORT's ROE is -0.01%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, AORT is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for AORT.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
AORT vs CNMD Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while CNMD trades at $46.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas CNMD's P/E ratio is 10.26. In terms of profitability, AORT's ROE is -0.01%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, AORT is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for AORT.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
AORT vs HSKA Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas HSKA's P/E ratio is -62.49. In terms of profitability, AORT's ROE is -0.01%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, AORT is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for AORT.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
AORT vs IART Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while IART trades at $16.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas IART's P/E ratio is 7.05. In terms of profitability, AORT's ROE is -0.01%, compared to IART's ROE of -0.01%. Regarding short-term risk, AORT is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for AORT.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
AORT vs AVNS Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas AVNS's P/E ratio is 27.77. In terms of profitability, AORT's ROE is -0.01%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, AORT is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for AORT.Check AVNS's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
AORT vs TNDM Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while TNDM trades at $16.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas TNDM's P/E ratio is -17.82. In terms of profitability, AORT's ROE is -0.01%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, AORT is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for AORT.Check TNDM's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
AORT vs SILK Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas SILK's P/E ratio is -18.96. In terms of profitability, AORT's ROE is -0.01%, compared to SILK's ROE of -0.35%. Regarding short-term risk, AORT is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
AORT vs IRMD Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while IRMD trades at $86.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas IRMD's P/E ratio is 43.45. In terms of profitability, AORT's ROE is -0.01%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, AORT is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for AORT.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
AORT vs FNA Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas FNA's P/E ratio is -19.83. In terms of profitability, AORT's ROE is -0.01%, compared to FNA's ROE of -0.35%. Regarding short-term risk, AORT is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for AORT.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
AORT vs ENOV Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ENOV trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ENOV's P/E ratio is 5.29. In terms of profitability, AORT's ROE is -0.01%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, AORT is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for AORT.Check ENOV's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
AORT vs PRCT Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while PRCT trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas PRCT's P/E ratio is -9.39. In terms of profitability, AORT's ROE is -0.01%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, AORT is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for AORT.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
AORT vs LMRI Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, LMRI has a market cap of 985.8M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while LMRI trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas LMRI's P/E ratio is -19.96. In terms of profitability, AORT's ROE is -0.01%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, AORT is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for AORT.Check LMRI's competition here
Bioventus Inc. (NASDAQ: BVS)
AORT vs BVS Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, BVS has a market cap of 948.5M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while BVS trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas BVS's P/E ratio is 18.42. In terms of profitability, AORT's ROE is -0.01%, compared to BVS's ROE of +0.28%. Regarding short-term risk, AORT is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for AORT.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
AORT vs CBLL Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, CBLL has a market cap of 943.3M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while CBLL trades at $24.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas CBLL's P/E ratio is -14.12. In terms of profitability, AORT's ROE is -0.01%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, AORT is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for AORT.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
AORT vs BBNX Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, BBNX has a market cap of 873.2M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while BBNX trades at $19.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas BBNX's P/E ratio is -11.76. In terms of profitability, AORT's ROE is -0.01%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, AORT is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for AORT.Check BBNX's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
AORT vs SIBN Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, SIBN has a market cap of 849.3M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while SIBN trades at $19.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas SIBN's P/E ratio is -56.32. In terms of profitability, AORT's ROE is -0.01%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, AORT is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for AORT.Check SIBN's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
AORT vs CSII Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas CSII's P/E ratio is -20.83. In terms of profitability, AORT's ROE is -0.01%, compared to CSII's ROE of -0.14%. Regarding short-term risk, AORT is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for AORT.Check CSII's competition here
InMode Ltd. (NASDAQ: INMD)
AORT vs INMD Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, INMD has a market cap of 817.4M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while INMD trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas INMD's P/E ratio is 9.88. In terms of profitability, AORT's ROE is -0.01%, compared to INMD's ROE of +0.12%. Regarding short-term risk, AORT is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
AORT vs VREX Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, VREX has a market cap of 777.6M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while VREX trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas VREX's P/E ratio is 19.44. In terms of profitability, AORT's ROE is -0.01%, compared to VREX's ROE of +0.05%. Regarding short-term risk, AORT is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for AORT.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
AORT vs AHCO Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, AHCO has a market cap of 771.4M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while AHCO trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas AHCO's P/E ratio is 11.57. In terms of profitability, AORT's ROE is -0.01%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, AORT is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for AORT.Check AHCO's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
AORT vs CTKB Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, CTKB has a market cap of 743.9M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while CTKB trades at $5.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas CTKB's P/E ratio is -30.51. In terms of profitability, AORT's ROE is -0.01%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, AORT is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for AORT.Check CTKB's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
AORT vs AVR Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, AVR has a market cap of 738M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while AVR trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas AVR's P/E ratio is -3.91. In terms of profitability, AORT's ROE is -0.01%, compared to AVR's ROE of -0.78%. Regarding short-term risk, AORT is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for AORT.Check AVR's competition here
Surmodics, Inc. (NASDAQ: SRDX)
AORT vs SRDX Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas SRDX's P/E ratio is -34.66. In terms of profitability, AORT's ROE is -0.01%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, AORT is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SRDX's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
AORT vs KIDS Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, KIDS has a market cap of 584.6M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while KIDS trades at $22.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas KIDS's P/E ratio is -19.29. In terms of profitability, AORT's ROE is -0.01%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, AORT is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for AORT.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
AORT vs APEN Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas APEN's P/E ratio is -9.43. In terms of profitability, AORT's ROE is -0.01%, compared to APEN's ROE of -0.85%. Regarding short-term risk, AORT is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for AORT.Check APEN's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
AORT vs SSII Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, SSII has a market cap of 578.4M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while SSII trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas SSII's P/E ratio is -48.17. In terms of profitability, AORT's ROE is -0.01%, compared to SSII's ROE of -0.27%. Regarding short-term risk, AORT is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for AORT.Check SSII's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
AORT vs PACB Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, PACB has a market cap of 568.4M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while PACB trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas PACB's P/E ratio is -4.46. In terms of profitability, AORT's ROE is -0.01%, compared to PACB's ROE of -49.62%. Regarding short-term risk, AORT is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for AORT.Check PACB's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
AORT vs DCTH Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, DCTH has a market cap of 547.2M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while DCTH trades at $15.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas DCTH's P/E ratio is 1585.00. In terms of profitability, AORT's ROE is -0.01%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, AORT is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for AORT.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
AORT vs ZIMV Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, AORT's ROE is -0.01%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, AORT is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ZIMV's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
AORT vs SGHT Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, SGHT has a market cap of 508.7M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while SGHT trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas SGHT's P/E ratio is -16.70. In terms of profitability, AORT's ROE is -0.01%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, AORT is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for AORT.Check SGHT's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
AORT vs TCMD Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, TCMD has a market cap of 508.2M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while TCMD trades at $22.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas TCMD's P/E ratio is 20.86. In terms of profitability, AORT's ROE is -0.01%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, AORT is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for AORT.Check TCMD's competition here
Cerus Corporation (NASDAQ: CERS)
AORT vs CERS Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, CERS has a market cap of 497.8M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while CERS trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas CERS's P/E ratio is -82.06. In terms of profitability, AORT's ROE is -0.01%, compared to CERS's ROE of -0.10%. Regarding short-term risk, AORT is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for AORT.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
AORT vs NPCE Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, NPCE has a market cap of 475.3M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while NPCE trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas NPCE's P/E ratio is -24.46. In terms of profitability, AORT's ROE is -0.01%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, AORT is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for AORT.Check NPCE's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
AORT vs SENS Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, SENS has a market cap of 420M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while SENS trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas SENS's P/E ratio is -4.51. In terms of profitability, AORT's ROE is -0.01%, compared to SENS's ROE of -1.66%. Regarding short-term risk, AORT is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for AORT.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
AORT vs OFIX Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, OFIX has a market cap of 394.1M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while OFIX trades at $9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas OFIX's P/E ratio is -6.35. In terms of profitability, AORT's ROE is -0.01%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, AORT is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for AORT.Check OFIX's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
AORT vs CLPT Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, CLPT has a market cap of 353M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while CLPT trades at $11.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas CLPT's P/E ratio is -9.97. In terms of profitability, AORT's ROE is -0.01%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, AORT is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for AORT.Check CLPT's competition here
CapsoVision, Inc. (NASDAQ: CV)
AORT vs CV Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, CV has a market cap of 334.3M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while CV trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas CV's P/E ratio is -10.62. In terms of profitability, AORT's ROE is -0.01%, compared to CV's ROE of -1.78%. Regarding short-term risk, AORT is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for AORT.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
AORT vs SMLR Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas SMLR's P/E ratio is 3.92. In terms of profitability, AORT's ROE is -0.01%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, AORT is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for AORT.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
AORT vs TMCI Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, TMCI has a market cap of 299.7M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while TMCI trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas TMCI's P/E ratio is -4.91. In terms of profitability, AORT's ROE is -0.01%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, AORT is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for AORT.Check TMCI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
AORT vs CATX Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, CATX has a market cap of 298.8M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while CATX trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas CATX's P/E ratio is -1.97. In terms of profitability, AORT's ROE is -0.01%, compared to CATX's ROE of -0.42%. Regarding short-term risk, AORT is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for AORT.Check CATX's competition here
Avita Medical Inc. (NASDAQ: RCEL)
AORT vs RCEL Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, RCEL has a market cap of 297.1M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while RCEL trades at $11.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas RCEL's P/E ratio is -8.31. In terms of profitability, AORT's ROE is -0.01%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, AORT is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for AORT.Check RCEL's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
AORT vs INFU Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, INFU has a market cap of 263M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while INFU trades at $13.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas INFU's P/E ratio is 31.78. In terms of profitability, AORT's ROE is -0.01%, compared to INFU's ROE of +0.15%. Regarding short-term risk, AORT is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for AORT.Check INFU's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
AORT vs TLSI Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, TLSI has a market cap of 261.7M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while TLSI trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas TLSI's P/E ratio is -2.53. In terms of profitability, AORT's ROE is -0.01%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, AORT is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for AORT.Check TLSI's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
AORT vs MGRM Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas MGRM's P/E ratio is -12.00. In terms of profitability, AORT's ROE is -0.01%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, AORT is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for AORT.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
AORT vs ELMD Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ELMD has a market cap of 232.9M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ELMD trades at $28.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ELMD's P/E ratio is 21.47. In terms of profitability, AORT's ROE is -0.01%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, AORT is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for AORT.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
AORT vs NVRO Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas NVRO's P/E ratio is -1.91. In terms of profitability, AORT's ROE is -0.01%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, AORT is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for AORT.Check NVRO's competition here
Profound Medical Corp. (NASDAQ: PROF)
AORT vs PROF Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, PROF has a market cap of 207.9M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while PROF trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas PROF's P/E ratio is -5.84. In terms of profitability, AORT's ROE is -0.01%, compared to PROF's ROE of -0.56%. Regarding short-term risk, AORT is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for AORT.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
AORT vs RXST Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, RXST has a market cap of 197.5M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while RXST trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas RXST's P/E ratio is -4.22. In terms of profitability, AORT's ROE is -0.01%, compared to RXST's ROE of -0.17%. Regarding short-term risk, AORT is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for AORT.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
AORT vs BSGM Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas BSGM's P/E ratio is -5.81. In terms of profitability, AORT's ROE is -0.01%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, AORT is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for AORT.Check BSGM's competition here
Quantum-Si incorporated (NASDAQ: QSI)
AORT vs QSI Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, QSI has a market cap of 189.5M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while QSI trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas QSI's P/E ratio is -2.08. In terms of profitability, AORT's ROE is -0.01%, compared to QSI's ROE of -0.47%. Regarding short-term risk, AORT is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for AORT.Check QSI's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
AORT vs MDGS Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas MDGS's P/E ratio is -0.27. In terms of profitability, AORT's ROE is -0.01%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, AORT is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for AORT.Check MDGS's competition here
Quanterix Corporation (NASDAQ: QTRX)
AORT vs QTRX Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, QTRX has a market cap of 172.9M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while QTRX trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas QTRX's P/E ratio is -1.44. In terms of profitability, AORT's ROE is -0.01%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, AORT is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for AORT.Check QTRX's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
AORT vs FOCL Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, FOCL has a market cap of 170.2M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while FOCL trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas FOCL's P/E ratio is -4.39. In terms of profitability, AORT's ROE is -0.01%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, AORT is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for AORT.Check FOCL's competition here
Neuronetics, Inc. (NASDAQ: STIM)
AORT vs STIM Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, STIM has a market cap of 164.2M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while STIM trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas STIM's P/E ratio is -5.36. In terms of profitability, AORT's ROE is -0.01%, compared to STIM's ROE of -1.51%. Regarding short-term risk, AORT is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for AORT.Check STIM's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
AORT vs QIPT Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas QIPT's P/E ratio is -15.87. In terms of profitability, AORT's ROE is -0.01%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, AORT is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for AORT.Check QIPT's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
AORT vs LUCD Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, LUCD has a market cap of 154.3M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while LUCD trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas LUCD's P/E ratio is -2.19. In terms of profitability, AORT's ROE is -0.01%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, AORT is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for AORT.Check LUCD's competition here
Inogen, Inc. (NASDAQ: INGN)
AORT vs INGN Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, INGN has a market cap of 145.4M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while INGN trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas INGN's P/E ratio is -5.90. In terms of profitability, AORT's ROE is -0.01%, compared to INGN's ROE of -0.13%. Regarding short-term risk, AORT is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for AORT.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
AORT vs ICAD Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ICAD's P/E ratio is -20.37. In terms of profitability, AORT's ROE is -0.01%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, AORT is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
AORT vs HJLI Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas HJLI's P/E ratio is N/A. In terms of profitability, AORT's ROE is -0.01%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, AORT is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for AORT.Check HJLI's competition here
electroCore, Inc. (NASDAQ: ECOR)
AORT vs ECOR Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ECOR has a market cap of 98.1M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ECOR trades at $10.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ECOR's P/E ratio is -6.48. In terms of profitability, AORT's ROE is -0.01%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, AORT is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for AORT.Check ECOR's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
AORT vs ASXC Comparison September 2026
Artivion, Inc. (NYSE: AORT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.1B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, AORT is priced at $22.86 on the NYSE, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of 38.07, whereas ASXC's P/E ratio is -1.12. In terms of profitability, AORT's ROE is -0.01%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, AORT is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for AORT.Check ASXC's competition here